The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein
Open accessAbstract
Key Ags of Mycobacterium tuberculosis initially identified in the context of host responses in healthy purified protein derivative-positive donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C-Mtb39-Mtb32N. Immunization of C57BL/6 mice with Mtb72F DNA resulted in the generation of IFN-γ responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with Mtb72F protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-γ response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of Mtb72F protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-γ and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of Mtb72F immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with Mtb72F, delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 year) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.
Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A., & Bloom, B. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2249 · Cited by 2,465
Disseminated tuberculosis in interferon gamma gene-disrupted mice.
Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., & Orme, I. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2243 · Cited by 1,986
Self-citationEfficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature
Colditz, G. A. (1994) · JAMA · doi:10.1001/jama.1994.03510330076038 · Cited by 1,918
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,199
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Flynn, J. L., Goldstein, M. M., Triebold, K. J., Koller, B., & Bloom, B. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12013 · Cited by 792
Global tuberculosis incidence and mortality during 1990-2000.
Pj, D., Raviglione, M. C., & Kochi, A. (1994) · PubMed · Cited by 768
Kensil, C. R., Patel, U., Lennick, M., & Marciani, D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.431 · Cited by 654
Adjuvants for human vaccines—current status, problems and future prospects
Gupta, R. K., & Siber, G. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00011-o · Cited by 551
Tuberculosis: a global overview of the situation today.
Sudre, P., ten Dam, G., & Kochi, A. (1992) · Europe PMC (PubMed Central) · Cited by 539
Jouanguy, E., Lamhamedi-Cherradi, S., Lammas, D., Dorman, S. E., Fondanèche, M.-C., Dupuis, S., Döffinger, R., Altare, F., Girdlestone, J., Emile, J.-F., et al. (1999) · Nature Genetics · doi:10.1038/7701 · Cited by 492
Brandt, L., Feino Cunha, J., Weinreich Olsen, A., Chilima, B., Hirsch, P., Appelberg, R., & Andersen, P. (2002) · Infection and Immunity · doi:10.1128/iai.70.2.672-678.2002 · Cited by 453
Self-citationControl of latentMycobacterium tuberculosis infection is dependent on CD8 T cells
van Pinxteren, L. A. H., Cassidy, J. P., Smedegaard, B. H. C., Agger, E. M., & Andersen, P. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3689::aid-immu3689>3.0.co;2-4 · Cited by 366
Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1576 · Cited by 327
Orme, I. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.1.293 · Cited by 314
Self-citationThe BCG Story: Lessons from the Past and Implications for the Future
Fine, P. E. M. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.supplement_2.s353 · Cited by 295
Müller, I., Cobbold, S. P., Waldmann, H., & Kaufmann, S. H. (1987) · Infection and Immunity · doi:10.1128/iai.55.9.2037-2041.1987 · Cited by 286
Drachenberg, K. J., Wheeler, A. W., Stuebner, P., & Horak, F. (2001) · Allergy · doi:10.1034/j.1398-9995.2001.056006498.x · Cited by 285
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich, J. T., & Myers, K. R. (1995) · PubMed · Cited by 278
Evaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis
Baldwin, S. L., D’Souza, C., Roberts, A. D., Kelly, B. P., Frank, A. A., Lui, M. A., Ulmer, J. B., Huygen, K., McMurray, D. M., & Orme, I. M. (1998) · Infection and Immunity · doi:10.1128/iai.66.6.2951-2959.1998 · Cited by 272
Self-citationImportance of thymus-derived lymphocytes in cell-mediated immunity to infection
North, R. J. (1973) · Cellular Immunology · doi:10.1016/0008-8749(73)90193-7 · Cited by 264
Taking toll: lipid A mimetics as adjuvants and immunomodulators
Persing, D. H., Coler, R. N., Lacy, M. J., Johnson, D. A., Baldridge, J. R., Hershberg, R. M., & Reed, S. G. (2002) · Trends in Microbiology · doi:10.1016/s0966-842x(02)02426-5 · Cited by 258
Self-citationEnhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., & Baldridge, J. R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.219 · Cited by 243
Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine
Stoute, J. A., Kester, K. E., Krzych, U., Wellde, B. T., Hall, T., White, K., Glenn, G., Ockenhouse, C. F., Garcon, N., Schwenk, R., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515657 · Cited by 236
Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions
Ulrich, J. T., & Myers, K. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_21 · Cited by 222
Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A
Martin, M., Michalek, S. M., & Katz, J. (2003) · Infection and Immunity · doi:10.1128/iai.71.5.2498-2507.2003 · Cited by 178
SKEIKY, Y. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00302-x · Cited by 172
Self-citationMarchand, M., Punt, C. J. A., Aamdal, S., Escudier, B., Kruit, W. H. J., Keilholz, U., Håkansson, L., van Baren, N., Humblet, Y., Mulders, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00479-3 · Cited by 169
Turner, O. C., Basaraba, R. J., & Orme, I. M. (2003) · Infection and Immunity · doi:10.1128/iai.71.2.864-871.2003 · Cited by 169
Self-citationMonophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines
Baldridge, J. R., & Crane, R. T. (1999) · Methods · doi:10.1006/meth.1999.0834 · Cited by 168
Dillon, D. C., Alderson, M. R., Day, C. H., Lewinsohn, D. M., Coler, R. N., Bement, T., Campos‐Neto, A., Skeiky, Y. A. W., Orme, I. M., Roberts, A. D., et al. (1999) · Infection and Immunity · doi:10.1128/iai.67.6.2941-2950.1999 · Cited by 159
Self-citationSafety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
Thoelen, S., Damme, P. V., Matheï, C., Leroux-Roels, G. G., Desombere, I., Safary, A., Vandepapelière, P., Slaoui, M., & Meheus, A. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00254-5 · Cited by 156
Structural and Immunological Characterization of the Vaccine Adjuvant QS-21
Kensil, C. R., Wu, J., & Soltysik, S. (1995) · Pharmaceutical biotechnology · doi:10.1007/978-1-4615-1823-5_22 · Cited by 139
Disease model: pulmonary tuberculosis
McMurray, D. N. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(00)01901-8 · Cited by 139
Kochi, A. (2001) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862001000100014 · Cited by 128
Dillon, D. C., Alderson, M. R., Day, C. H., Bement, T., Campos‐Neto, A., Skeiky, Y. A. W., Vedvick, T., Badaró, R. J. D. S., Reed, S. G., & Houghton, R. L. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3285-3290.2000 · Cited by 124
Self-citationAlderson, M. R., Bement, T., Day, C. H., Zhu, L., Molesh, D. A., Skeiky, Y. A. W., Coler, R. N., Lewinsohn, D. M., Reed, S. G., & Dillon, D. C. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.551 · Cited by 119
Self-citationSkeiky, Y. A. W., Lodes, M. J., Guderian, J. A., Mohamath, R., Bement, T., Alderson, M. R., & Reed, S. G. (1999) · Infection and Immunity · doi:10.1128/iai.67.8.3998-4007.1999 · Cited by 118
Self-citationQS-21 structure/function studies: effect of acylation on adjuvant activity
Liu, G., Anderson, C., Scaltreto, H., Barbon, J., & Kensil, C. R. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00209-8 · Cited by 114
Brewer, T. F., & Colditz, G. A. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.126 · Cited by 112
Pathogenesis of Experimental Tuberculosis in Animal Models
McMurray, D. N., Collins, F. M., Dannenberg, A. M., & Smith, D. W. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-80166-2_7 · Cited by 106
Angov, E., Aufiero, B. M., Turgeon, A. M., Handenhove, M. V., Ockenhouse, C. F., Kester, K. E., Walsh, D. S., McBride, J. S., Dubois, M., Cohen, J., et al. (2003) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(03)00077-x · Cited by 94
Voss, G., Manson, K. H., Montefiori, D. C., Watkins, D. I., Heeney, J. L., Wyand, M. S., Cohen, J., & Bruck, C. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1049-1058.2003 · Cited by 67
Mikloška, Z., Rückholdt, M., Ghadiminejad, I., Dunckley, H., Denis, M., & Cunningham, A. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5167 · Cited by 64
McCormack, S., Tilzey, A., Carmichael, A. J., Gotch, F., Kepple, J., Newberry, A. M., Jones, G. J., Lister, S. G., Beddows, S. A., CHEINGSONG-POPOV, R., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00388-6 · Cited by 58
Lodes, M. J., Dillon, D. C., Mohamath, R., Day, C. H., Benson, D. R., Reynolds, L. D., McNeill, P. D., Pedral-Sampaio, D., Skeiky, Y. A. W., Badaró, R. J. D. S., et al. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2485-2493.2001 · Cited by 47
Self-citationThe tuberculosis epidemic. Scientific challenges and opportunities.
Ginsberg, A. (1998) · Europe PMC (PubMed Central) · Cited by 40
Baldrick, P., Richardson, D., & Wheeler, A. W. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00413-3 · Cited by 31
A coordinated strategy for evaluating new vaccines for human and animal tuberculosis
McMurray, D. N. (2001) · Tuberculosis · doi:10.1054/tube.2000.0265 · Cited by 29
Cited by
The success and failure of BCG — implications for a novel tuberculosis vaccine
Andersen, P., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 788
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
Aagaard, C., Hoang, T., Dietrich, J., Cardona, P.-J., Izzo, A., Dolganov, G., Schoolnik, G. K., Cassidy, J. P., Billeskov, R., & Andersen, P. (2011) · Nature Medicine · doi:10.1038/nm.2285 · Cited by 527
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationNewton, S. M., Brent, A. J., Anderson, S., Whittaker, E., & Kampmann, B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70182-8 · Cited by 480
Metadata
- Authors
- Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., & Reed, S. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06
- Volume
- 172
- Issue
- 12
- Pages
- 7618-7628
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1582232949
- Cited by
- 313
- References
- 49
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.